ophthalmology-summit-2019-accepted-abstracts

Ophthalmology Summit 2019

Ophthalmology Case Reports | Volume 3

Note:

OF EXCELLENCE

IN INTERNATIONAL

MEETINGS

YEARS

March 27-28, 2019 | Amsterdam, Netherlands

GLOBAL

OPHTHALMOLOGY SUMMIT 2019

Page47

EFFICACYAND SAFETY OF SIMVASTATININ UVEITIS ASSOCIATEDWITH

HLAB27 AND/OR RHEUMATIC DISEASES: A RANDOMIZED, OPEN-LABEL

STUDY

Biryukova Anastasia

Academy of Medical Sciences of Russia, Russia

Introduction:

Statins have been shown to reduce ocular inflammation in animal models and to prevent devel-

opment of uveitis in observational studies. There have been no experimental human studies evaluating statins

efficacy and safety in uveitis.

Aim:

To investigate the efficacy and safetyof simvastatin in patients with uveitis associated with HLAB27 and/

or rheumatic diseases.

Methods:

For this single-center, open-label, randomized study, we enrolled patients with acute uveitis, as-

sociated with HLAB27/rheumatic diseases. The patients were randomized to receive 40 mg simvastatin per

day for 2 months with the local anti-inflammatorytreatmentor to local anti-inflammatory therapy alone. The

studied outcomes were: visual acuity (letters score) conjunctival injection (grades 1-5) and anterior chamber

reaction (grades 1-5), the frequency of visual field impairment and posterior synechia. Generalized estimating

equations were used to model the relationship between simvastatin use by time interaction and changes in

the outcome measures.

Results:

Forty five patients were enrolled in the study. Twenty two (49%) of them were positive for HLA-B27

without extraocular manifestations, 18 (40%)had concomitant seronegative spondyloarthritis, 4 (9%) hadjuve-

nile idiopathic arthritis and 1 (2%) was diagnosed with Behcet’s disease. Twenty nine (64%) patients had inter-

mediate uveitis, 13 (29%) anterior uveitis and 3 (7%) panuveitis. Twenty two patients were randomly assigned

to receive simvastatinwith local treatment and 23 to local treatment alone. Simvastatin was associated with

significant improvement in visual acuity, conjunctival injection, andanterior chamber reaction. In patients

treated with simvastatin the rates of posterior synechia and visual field impairment were less than in control

group (Table). The treatment was well tolerated, only mild side effects were observed.

Conclusions:

Our findings suggest that statins may have therapeutic potential in uveitis. These results should

be confirmed in a double blind, randomized, controlled study.

Ophthalmol Case Rep 2019, Volume 3